08:00 , Nov 8, 2010 |  BC Week In Review  |  Clinical News

APD597: Phase I data

Arena reported data from its Phase I program of APD597 showing that single and multiple ascending-doses of the compound were well tolerated in healthy volunteers and Type II diabetics. Additionally, APD597 in combination with ...
08:00 , Nov 8, 2010 |  BioCentury  |  Finance

Regulatory milestones

Regulatory milestones Adventrx Pharmaceuticals Inc. (NYSE-A:ANX) lost $0.03 to $2.07 last week after resubmitting an NDA to FDA for Exelbine vinorelbine injectable emulsion to treat non-small cell lung cancer (NSCLC). The company said the submission included...
08:00 , Nov 8, 2010 |  BC Week In Review  |  Company News

Arena, J&J deal

Johnson & Johnson unit Ortho-McNeil-Janssen Pharmaceuticals Inc. will terminate a 2004 deal and return rights to APD597 to Arena. The glucose-dependent insulinotropic (GDI; 19AJ) receptor agonist completed Phase I testing for Type II diabetes. The...
00:26 , Nov 5, 2010 |  BC Extra  |  Company News

J&J unit ends diabetes deal with Arena

Johnson & Johnson (NYSE:JNJ) unit Ortho-McNeil-Janssen Pharmaceuticals Inc. will terminate a 2004 deal and return rights to diabetes candidate APD597 to Arena Pharmaceuticals Inc. (NASDAQ:ARNA). The glucose-dependent insulinotropic (GDI; 19AJ) receptor agonist has completed Phase...
07:00 , Aug 17, 2009 |  BC Week In Review  |  Clinical News

APD597 update

Arena disclosed that last quarter J&J's Ortho-McNeil-Janssen Pharmaceuticals Inc. unit began a multiple ascending-dose trial to evaluate oral APD597. Arena also said that its partner completed a single ascending-dose Phase I trial evaluating APD597 in...
08:00 , Dec 22, 2008 |  BC Week In Review  |  Clinical News

APD597: Phase I started

Arena began a single and multiple ascending-dose Phase I trial to evaluate oral APD597 in healthy volunteers. The company is developing GDIR agonists with J&J's Ortho-McNeil Pharmaceutical Inc. unit under a 2004 agreement (see...
08:00 , Jan 14, 2008 |  BC Week In Review  |  Clinical News

APD668: Interim Phase I data

Arena partner Johnson & Johnson placed development of APD668 on hold to focus on a more potent compound that is in preclinical development. The companies did say that in the APD668 Phase I program, which...
08:00 , Jan 14, 2008 |  BC Week In Review  |  Clinical News

GDIR agonist: Phase I start

In 2008, Johnson & Johnson's Ortho-McNeil Pharmaceutical Inc. unit will begin Phase I testing of an undisclosed GDIR agonist. The companies said the compound was more potent in preclinical models than APD668, another GDIR...
08:00 , Feb 5, 2007 |  BioCentury  |  Strategy

New diabetes targets

New diabetes targets Company Product Target Status sanofi-aventis Rimonabant (A) Cannabinoid CB1 receptor Ph III MacroGenics Teplizumab CD3 Ph II/III Bristol-Myers/AstraZeneca Dapagliflozin Sodium dependent glucose transport (SGLT2) Ph IIb Metabasis/Daiichi Sankyo CS-917 Fructose 1,6-bisphosphatase...
07:00 , Oct 2, 2006 |  BC Week In Review  |  Company News

Arena, J&J deal

JNJ's Ortho-McNeil Pharmaceutical Inc. unit extended for one year a 2004 deal with ARNA to develop compounds targeting the glucose-dependent insulinotropic (GDI) (19AJ) receptor to treat Type II diabetes (see BioCentury, Jan. 3,...